Por favor, use este identificador para citar o enlazar este ítem:
http://conacyt.repositorioinstitucional.mx/jspui/handle/1000/462| Serotype patterns of pneumococcal disease in adults are correlated with carriage patterns in older children | |
| Daniel M Weinberger Ron Dagan Noga Givon-Lavi Joshua L Warren Gili Regev-Yochay Anne Louise Wyllie | |
| Novel Coronavirus | |
| Acceso Abierto | |
| Atribución | |
| 10.1101/2019.12.18.19015180 | |
| Background: The importance of specific serotypes causing invasive pneumococcal disease (IPD) differs by age. Data on pneumococcal carriage in different age groups, along with data on serotype-specific invasiveness, could help to explain these age-related patterns and their implications for vaccination. Methods: Using pneumococcal carriage and disease data from Israel, we evaluated the association between serotype-specific IPD in adults and serotype-specific carriage prevalence among children in different age categories, while adjusting for serotype-specific invasiveness. We used a sliding window approach to estimate carriage prevalence using different age groupings. Deviance Information Criterion was used to determine which age groupings of carriage data best fit the adult IPD data. Serotype-specific disease patterns were further evaluated by stratifying IPD data by comorbidity status. Results: The relative frequency of serotypes causing IPD differed between adults and children, and also differed between older and younger adults and between adults with and without comorbidities. Serotypes over-represented as causes of IPD in adults were more commonly carried in older children as compared to younger children. In line with this, the serotype-specific frequency of carriage in older children (aged 36-59 months), rather than infants, best correlated with serotype-specific IPD in adults. Conclusions: These analyses suggest that older children, rather than infants, are the main drivers of disease patterns in adults. These insights could help in optimizing vaccination strategies to reduce disease burden across all ages. ### Competing Interest Statement ALW declares to have received consulting fees for participation in advisory boards for Pfizer. GRY has received consulting fees and research funding from Pfizer and research support from GSK. RD has received consulting fees from Pfizer, MSD and MeMed; research grants from Pfizer and MSD; and speaker fees from Pfizer. DMW has received consulting fees from Pfizer, Merck, GSK, and Affinivax and has received research funding through grants from Pfizer to Yale. All other co-authors declare no potential conflict of interest. ### Funding Statement This work was supported by the National Institutes of Health/National Institute of Allergy and Infectious Diseases [grant numbers R01-AI123208, R01-AI137093 to D.M.W]; and the Bill and Melinda Gates Foundation [grant number OPP1176267 to D.M.W]. The funding agencies were not involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication. ### Author Declarations All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript. Yes All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes Due to privacy, raw data analysed in the current study cannot be published. Please contact authors for queries regarding the datasets. | |
| Cold Spring Harbor Laboratory Press | |
| 2019 | |
| Preimpreso | |
| https://www.medrxiv.org/content/10.1101/2019.12.18.19015180v1 | |
| Inglés | |
| VIRUS RESPIRATORIOS | |
| Aparece en las colecciones: | Artículos científicos |
Cargar archivos:
| Fichero | Tamaño | Formato | |
|---|---|---|---|
| Serotype patterns of pneumococcal.pdf | 1.53 MB | Adobe PDF | Visualizar/Abrir |